ESHAP versus GEMOX in Management of Relapsed or Refractory Lymphoma: A Prospective Randomized Study
Background: There is lack of evidence about the best chemotherapy regimen in treatment of relapsed/refractory Hodgkin's<br />lymphoma (HL) and aggressive non-Hodgkin’s lymphoma (NHL) lymphoma.<br />Aim: To compare GEMOX (gemcitabine, oxaliplatin) with ESHAP (etoposide, methylprednisolone, cytarabine...
Tallennettuna:
| Päätekijät: | , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine
2018-06-01
|
| Sarja: | Research in Oncology |
| Aiheet: | |
| Linkit: | https://resoncol.journals.ekb.eg/article_5723_86a56012e17afb7b8d2cfdeb24680218.pdf |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|